RxDoctor Payments Data

Larry Blum, MD

Neurology · Glen Burnie, MDNPI 1053300962

Payments from drug & device makers

$6,192in general payments, 2019–2025

Across 268 payments — averaging $23.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$390
  • Amgen$388
  • UCB, Inc.$294
  • TG Therapeutics, Inc.$292
  • Lundbeck LLC$249
  • Novartis$241
  • plus $4K from 54 others

What the payments were for

  • Speaking & faculty fees$190%
  • Food & beverage$6,15699%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)16$390
Amgen(2 entities)19$388
UCB, Inc.12$294
TG Therapeutics, Inc.5$292
Lundbeck LLC9$249
Novartis10$241
Grifols USA, LLC8$222
CSL Behring10$216
Biogen10$213
Sanofi11$213
Neurelis, Inc.9$205
EMD Serono, Inc.9$202
AbbVie(2 entities)9$197
Pfizer10$193
Eisai Inc.9$181
Takeda Pharmaceuticals U.S.A., Inc.5$145
Neurocrine Biosciences, Inc.5$141
Lilly USA, LLC7$140
Tanabe Pharma America, Inc.6$133
Genentech USA, Inc.6$131
Bristol Myers Squibb8$124
E.r. Squibb & Sons, L.L.C.1$110
Averitas Pharma Inc.4$106
Banner Life Sciences, LLC4$93
Acadia Pharmaceuticals Inc6$92
Argenx US, Inc.3$83
Johnson & Johnson(2 entities)3$71
Teva Pharmaceuticals USA, Inc.4$68
Biohaven Pharmaceuticals, Inc.3$55
SK Life Science, Inc.2$53
Jazz Pharmaceuticals Inc.2$49
Upsher-smith Laboratories LLC2$49
Impel Pharmaceuticals LLC3$47
Catalyst Pharmaceuticals, Inc.2$47
MDD US Operations, LLC1$46
Biohaven Pharmaceutical Holding Company Ltd.2$44
Trevena, Inc.2$41
Vertical Pharmaceuticals, LLC2$39
Ultragenyx Pharmaceutical Inc.2$38
KCI USA, Inc.1$37
Arbor Pharmaceuticals, Inc.2$36
Avanir Pharmaceuticals, Inc.2$32
Adamas Pharmaceuticals, Inc.2$32
Livanova USA, Inc.1$28
Axsome Therapeutics, Inc.1$25
Cycle Pharmaceuticals Inc1$24
Impel Pharmaceuticals Inc.1$24
Vertos Medical, Inc.1$24
Mallinckrodt Enterprises LLC1$24
Medtronic1$23
Solventum Corporation1$23
Radius Health, Inc.1$23
Supreme Orthopedic Systems, LLC1$21
Boston Scientific1$20
Smith+Nephew1$20
Intrinsic Therapeutics1$19
Acorda Therapeutics, Inc1$19
Akcea Therapeutics, Inc.1$18
Azurity Pharmaceuticals, Inc.1$18
Sunovion Pharmaceuticals Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,192 in reported general payments places this provider in the 60th percentile of 442 neurology providers in Maryland.

See all neurology providers in Maryland

Medicare billing

Part B allowed, 2024
$70,037
Medicare patients
356
Services billed
651

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SolirisEculizumab12$586,404
UbrelvyUbrogepant23$33,756
Nurtec OdtRimegepant Sulfate14$15,574
QuliptaAtogepant11$11,640
EliquisApixaban12$7,966
Lacosamide47$7,188
Memantine Hcl167$6,006
Levetiracetam108$4,221
Gabapentin186$3,431
Pregabalin55$2,836
Donepezil Hcl193$2,220
Oxcarbazepine30$1,879
AmantadineAmantadine Hcl42$1,726
Lamotrigine OdtLamotrigine12$1,503
Carbidopa-LevodopaCarbidopa/Levodopa65$1,272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSoliris$390$586,40412 claims
AbbVieUbrelvy, Qulipta$197$45,39734 claims
PfizerNurtec Odt, Eliquis$193$23,54026 claims
Upsher-smith Laboratories LLCTopiramate$49$36822 claims
Lilly USA, LLCOlanzapine$140$11724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 442 neurology providers in Maryland.

Other neurology in Glen Burnie

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →